Theravance Biopharma, Inc. (NASDAQ:TBPH)
| Market Cap | 882.64M+17.9% |
| Revenue (ttm) | 104.31M+35.1% |
| Net Income | 53.81M+312.9% |
| EPS | 1.01+322.4% |
| Shares Out | 51.92M |
| PE Ratio | 16.01 |
| Forward PE | 9.13 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,016,289 |
| Open | 17.05 |
| Previous Close | 17.03 |
| Day's Range | 17.02 - 17.07 |
| 52-Week Range | 13.08 - 21.03 |
| Beta | 0.17 |
| Analysts | Hold |
| Price Target | 17.00(-0.18%) |
| Earnings Date | Nov 10, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About TBPH
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$TBPH stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in TBPH holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by TBPH's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
TBPH Estimated quarterly lobbying spending
Source: U.S. Senate LDA
TBPH Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New TBPH patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to TBPH from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in TBPH
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $22.08M |
| VXFVanguard Extended Market ETF | $7.40M |
| VETSPacer Military Times Best Employers ETF | $4.85M |
| VTWOVanguard Russell 2000 ETF | $3.96M |
| VHTVanguard Health Care ETF | $2.01M |
| VTWGVanguard Russell 2000 Growth ETF | $638.25K |
Estimated from each fund’s disclosed top holdings × AUM
TBPH Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from TBPH’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score